FN2 Earnings Intelligence
West Pharmaceutical Services, Inc. earnings overview
Latest West Pharmaceutical Services, Inc. (WST) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
West Pharmaceutical Services, Inc.
West Pharmaceutical Services delivered a second consecutive quarter of beats-and-raises in Q2 2026, with revenue of $872 million (up 13% YoY) and adjusted EPS of $2.37 (up 29% YoY), both above consensus. The company raised full-year guidance for the second time, now projecting 10-11% organic revenue growth and adjusted EPS of $8.85-$9.05. Growth continues to be driven by high-value proprietary (HVP) components -- particularly biologics, GLP-1 elastomers, and Annex 1 upgrade projects -- which now represent approximately 49% of total revenue and carry higher margins. The completed SmartDose divestiture removes a dilutive product line, while the renewed Daikyo partnership and approximately 800 Annex 1 upgrade projects (up 50% YoY) support a multiyear growth thesis. A cyber incident temporarily dragged the West Vantage segment, but management expects H2 recovery. CEO succession is…
West Pharmaceutical Services, Inc.
The quarter supports a constructive view of West Pharma's growth trajectory: demand for GLP-1-related components, biologics and Annex 1 upgrades drove a guidance increase. The next test is whether capacity expansion and operational improvements can sustain growth and margins as commodity and regulatory risks persist.
West Pharmaceutical Services, Inc.
The supplied analysis provides evidence for a constructive one-year operating outlook: management cited HVP, biologics, biosimilars and Annex 1 demand, maintained FY2026 growth guidance, and is expanding capacity while reducing capex. The thesis is not risk-free because supply constraints, oral GLP-1 substitution and regulatory or tariff exposure could limit delivery.
West Pharmaceutical Services, Inc.
The evidence supports a constructive operating trajectory: resilient HVP-related demand, capacity investments and a favorable mix shift underpin growth and margins. The thesis depends on executing the CGM back-fill and converting Annex 1 projects on schedule.
West Pharmaceutical Services, Inc.
The quarter supports a constructive operating thesis: resilient HVP and GLP-1 demand, favorable mix, and capacity investment are supporting growth and a higher outlook. The thesis depends on converting capacity projects while containing destocking, labor, tariff, and automation risks.
West Pharmaceutical Services, Inc.
The supplied analysis supports a constructive operating trajectory: resilient GLP-1 and HVP demand, accelerating AnnexOne work, and capacity investments led management to raise guidance. The case is tempered by tariffs, FX, supply constraints, pricing, mix, and facility-execution risks.
West Pharmaceutical Services, Inc.
The supplied analysis supports a mixed view: demand and capacity investments in HPP, GLP-1 packaging, biologics and SmartDose provide growth avenues, but lower-margin mix, CGM exits, FX and execution risks make near-term earnings conversion less certain.
West Pharmaceutical Services, Inc.
West Pharma's raised outlook and resilient demand in biologics, GLP-1 contract manufacturing and wearable injection devices support a constructive operating trajectory. The case still depends on destocking normalization, mix improvement and execution of new capacity and automation.
Get the WST recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.